Vaccine Info

GOVX-B11 HIV Vaccine

GOVX-B11 HIV Vaccine Description

GOVX-B11 is a Clade B HIV vaccine candidate targeted for use in the Americas, Europe, Japan, and Australia.

GOVX-B11 is a vaccine candidate that uses recombinant DNA and recombinant modified vaccinia Ankara (MVA) vaccines to express non-infectious virus-like particles. 

The GOVX-B11 vaccine consists of a recombinant DNA vaccine used to prime immune responses and a recombinant MVA vaccine used to boost the primed responses.

GOVX-B11 HIV Vaccine Indication

GOVX-B11 is indicated to prevent HIV disease

GOVX-B11 HIV Vaccine Dosage

The proposed regimen for the Phase 2b efficacy trial consists of DNA delivered into the muscle with a needle and syringe at 0 and 2 months and MVA delivered into the muscle with a needle and syringe at 4, 6 and 10 months (DDMM_M regimen).

GOVX-B11 HIV Vaccine Clinical Trials

 

 

Updated
02/14/2020 - 13:51